-
Gilead Sciences (GILD): Taking Stock of Valuation as Shares Approach Analyst Targets
20 Nov 2025 02:38 GMT
… our latest analysis for Gilead Sciences. Gilead Sciences has enjoyed a wave … list for free. With shares now trading just a … Gilead Sciences. Find out about the key risks to this Gilead Sciences … starting point for your Gilead Sciences research is our analysis …
-
Gilead Sciences Announces Third Quarter 2025 Financial Results
31 Oct 2025 07:02 GMT
… the accompanying tables. About Gilead Sciences Gilead Sciences, Inc. is a … including the following: GILEAD®, Gilead Sciences®, KITE®, AMBISOME®, ATRIPLA®, BIKTARVY … 246 shares of common stock issued and outstanding, respectively. Gilead Sciences, …
-
A Glimpse of Gilead Sciences's Earnings Potential
29 Oct 2025 14:57 GMT
… 7.00
Stock Performance
Shares of Gilead Sciences were trading at $117 … Gilead Sciences is at the bottom.
Delving into Gilead Sciences's Background
Gilead Sciences … therapy Trodelvy (from Immunomedics).
Gilead Sciences: A Financial Overview
Market …
-
Gilead Sciences Breaks Out To Record Highs, The Rally Has Room To Run
19 Oct 2025 04:57 GMT
Gilead Sciences (GILD) is a top-performing … ;iStock Editorial via Getty Images Gilead Sciences (NASDAQ:GILD) is among the … 2025. So far this year, shares are up 36%, dividends included …
-
Is Tango Therapeutics Stock a Buy, Sell, or Hold After Major Shareholder Third Rock Ventures Sold Nearly Half a Million Shares?
31 Oct 2025 09:02 GMT
… .
Transaction summary
Metric
Value
Shares sold
477,401
Transaction value … maintains strategic collaborations, notably with Gilead Sciences. Tango Therapeutics serves pharmaceutical … venture capital fund shedding some shares makes sense. Tango Therapeutics …
-
Gilead Sciences Settles Patent Litigations With Generic Drugmakers For Best-Selling HIV Drug: Analyst Cheers Longer Runway
06 Oct 2025 21:01 GMT
Gilead Sciences (GILD) announced on Monday that … market generic versions of Biktarvy.
Shares of the company rose marginally …
-
JPMorgan Lifts Gilead Sciences, Inc. (GILD)’s Price Target To $145, Maintains Overweight Rating
26 Sep 2025 14:57 GMT
Gilead Sciences, Inc. (NASDAQ:GILD) is … Overweight rating for its shares. JPMorgan Lifts Gilead Sciences, Inc. (GILD)… a 29% upside potential for Gilead Sciences, Inc. (NASDAQ:GILD) from … with a consensus Buy rating. Gilead Sciences, Inc. (NASDAQ:GILD) is …
-
<![CDATA[Matthew Galsky, MD, shares 5-year data from CheckMate 274 in MIUC ]]>
18 Oct 2025 15:01 GMT
“With extended follow-up, 5 years of follow-up, there is a sustained benefit of adjuvant nivolumab vs placebo for disease-free survival in both the all randomized patient population and in patients with tumors with high levels of PD-L1 expression,” Galsky …
-
SLB, Apple, Nvidia, Merck, Gilead Sciences: What Sparked Heavy After-Hours Trading In These 5 Stocks?
11 Sep 2025 06:55 GMT
… Houston, Texas-based company’s shares rose over 1% on Wednesday … . ET, Sept. 11 | source: StocktwitsThe shares of the artificial intelligence chipmaker … | source: StocktwitsRetail sentiment toward the Gilead Sciences stock remained ‘neutral’ (47…
-
RBC Capital Sticks to Their Hold Rating for Gilead Sciences (GILD)
05 Sep 2025 08:19 GMT
… Gilead Sciences, with a price target of $98.00. The company’s shares … Buy analyst consensus rating for Gilead Sciences with a $125.77 average … low of $77.74. Currently, Gilead Sciences has an average volume of …
About
© 1995-2025